Spinal Muscular Atrophy Therapies: ICER Grounds the Price to Value Conversation in Facts.

Abstract

DISCLOSURES\nNo funding supported the writing of this commentary. The authors are employed by Prime Therapeutics, a pharmacy benefits management company.